BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

...The company's first candidate is AMO-01 , a farnesylated dibenzodiazepinone in development for fragile X. AMO-01...
...TSPO ; PBR ), expressed on activated astrocytes, and inhibits the Ras-ERK pathway. AMO licensed AMO-01...
...AMO-01 to other clinical candidates, but cited Neuren Pharmaceuticals Ltd .'s trofinetide as one of AMO-01's...
BioCentury | Oct 1, 2015
Financial News

Woodford backs AMO in $25M series A round

...year of lead candidate AMO-02 to treat myotonic dystrophy type 1 (DM1, Steinert's disease) and AMO-01...
...has undergone clinical testing for Alzheimer's disease and progressive supranuclear palsy. AMO also in-licensed AMO-01...
...inhibitor of the Ras extracellular signal-regulated kinase pathway (Ras-ERK); AMO declined to disclose the licensor. AMO-01...
BioCentury | Jan 4, 2010
Clinical News

TLN-4601: Phase II discontinued

...showed that only 3 out of 17 evaluable patients treated with 480 mg/m 2/day IV TLN-4601...
...next steps for the TLN-4601 program. Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: TLN-4601 (formerly ECO-4601...
BioCentury | Jun 15, 2009
Company News

Thallion cancer news

...has negotiated with its suppliers and other commitments to save cash. Thallion's lead compound is TLN-4601...
...has negotiated with its suppliers and other commitments to save cash. Thallion's lead compound is TLN-4601...
BioCentury | Dec 15, 2008
Company News

Thallion cancer, infectious news

...undisclosed pharma. Thallion has three candidates in Phase II testing. Interim data from trials of TLN-4601...
BioCentury | Sep 29, 2008
Clinical News

TLN-4601: Phase II started

...began an open-label, North American Phase II trial to evaluate 480 mg/m 2/day of intravenous TLN-4601...
...line monotherapy (see BioCentury, May 19). Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: TLN-4601 (formerly ECO-4601...
BioCentury | May 19, 2008
Clinical News

TLN-4601: Phase II start

...American Phase II trial in up to 40 patients to evaluate 480mg/m 2/day of intravenous TLN-4601...
...week off in a 21-day cycle. Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: TLN-4601 (formerly ECO-4601...
BioCentury | Apr 14, 2008
Clinical News

TLN-4601: Phase II start

...TLN-4601 as monotherapy in 40 patients. Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: TLN-4601 (formerly ECO-4601...
BioCentury | Dec 3, 2007
Clinical News

Thallion preclinical data

...In a rat brain tumor model, the average concentration of ECO-4601 in the tumor was 176...
...Phase I/II testing to treat advanced solid tumors. Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: ECO-4601...
BioCentury | Dec 3, 2007
Clinical News

ECO-4601: Additional Phase I/II data

...the open-label, Canadian Phase I/II ECO-4601-101 trial in 26 advanced cancer patients showed that IV ECO-4601...
...mg/m 2. Six of 7 patients completing 6 treatment cycles achieved stable disease. Patients received ECO-4601...
...to 480 mg/m 2 (see BioCentury, Jan. 15). Thallion Pharmaceuticals Inc. (TSX:TLN), Montreal, Quebec Product: ECO-4601...
Items per page:
1 - 10 of 22